Close Menu
Canndoras Box
  • Home
  • History
  • Cannabis
  • Cannabis Tech
  • Hemp
  • CBD
  • THCA
  • News
  • Business
  • Cannabis Bust
    • Cannabis Pioneers

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

7 Best CBD Capsules of 2025

April 25, 2025

Best CBD Oils for Joint Pain in 2025

February 27, 2025

CBD CoP16 – What is CBD CoP16 and why is it important to rhinos?

October 31, 2024
Facebook X (Twitter) Instagram
Canndoras Box
  • Home
  • About Us
  • Advertise with Us
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • Home
  • History
  • Cannabis
  • Cannabis Tech
  • Hemp
  • CBD
  • THCA
  • News
  • Business
  • Cannabis Bust
    • Cannabis Pioneers
Canndoras Box
Home » DEA boosts research production of psychedelics, keeps marijuana quotas in place ahead of rescheduling
Cannabis

DEA boosts research production of psychedelics, keeps marijuana quotas in place ahead of rescheduling

adminBy adminSeptember 24, 2024No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


The Drug Enforcement Administration (DEA) has announced new production quotas for Schedule I and II controlled substances, with a particular focus on increasing the supply of certain hallucinogens for research purposes. As Marijuana Moment reports, substances targeted for increased production include psilocybin, psilocin, and ibogaine, reflecting growing scientific interest in their therapeutic properties. Meanwhile, marijuana production quotas remain unchanged as the agency prepares for a major decision on regulatory changes.

Increasing production of hallucinogens to support research

In its revised 2024 and newly proposed 2025 quotas, the DEA is proposing a significant increase in the production of psychedelic drugs such as psilocybin and psilocin. The 2024 quotas will increase to 30,000 grams and 36,000 grams, respectively, and will remain at those levels through 2025. Similarly, ibogaine production will increase from 150 grams to 210 grams in 2025 to meet growing research demand.

“These proposed increases are intended to support research and clinical trials conducted by DEA-registered Schedule I investigators,” the administration said. “DEA remains committed to ensuring that all patients with legitimate medical need have access to appropriately prescribed medicines.”

Cannabis quotas remain stable amid rescheduling considerations

While research opportunities are expanding in the psychedelic drug field, cannabis quotas remain unchanged. Beginning in 2023, the DEA is maintaining the marijuana total production quota (APQ) at 6.675 million grams, with no changes to quotas for other substances such as DMT, MDMA, LSD, and mescaline. This stabilization of cannabis production quotas comes as the DEA prepares to hold an administrative hearing in December to consider moving cannabis to Schedule III of the Controlled Substances Act.

Barriers to cannabis research likely to continue

Reclassifying cannabis would change how researchers can access the plant for research and could remove it from the annual APQ process. But as a recent Congressional Research Service report points out, reclassification alone may not fully ease research barriers. The report notes that even with a move to Schedule III, “medical researchers and pharmaceutical sponsors of drugs containing marijuana or CBD will not be able to benefit from these looser regulations that come with the reclassification without Congressional action.”

The prevalence of psychedelics in mental health treatment

The DEA's focus on psychedelic drug production comes at a time when studies and anecdotal reports, including from U.S. Rep. Morgan Luttrell (R-Texas), have highlighted the promise of psychedelics in treating serious mental illnesses. Ibogaine, for example, has been gaining attention as a potential treatment for addiction, and researchers and advocates have called on the DEA to support more research into it.

Amid these developments, the DEA is also set to address other psychedelic issues during a 10-day hearing on a proposed ban of two psychedelic compounds, DOI and DOC. The hearing comes on the heels of a federal court ruling that dismissed a lawsuit that challenged the DEA's scheduling process for those substances.

At the same time, the Food and Drug Administration recently rejected an application for an MDMA-assisted therapy, a decision that drew criticism on both sides of the aisle. Despite this setback, the increased attention on psychedelic drug research signals a major shift in the DEA’s approach to drug policy, particularly with regard to substances that may have therapeutic benefits.

AI-generated cover image

Market news and data provided by Benzinga API

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
admin
  • Website

Related Posts

Keep your kids safe from marijuana this Halloween

October 31, 2024

Cannabis and professional pickleball form first-ever sponsorship deal

October 30, 2024

Massachusetts cannabis regulator approves new industry rules

October 30, 2024
Leave A Reply Cancel Reply

Don't Miss
History

7 Best CBD Capsules of 2025

Tester Christine Karin tried the 100 mg version of the CBDMD softgel. She found it…

Best CBD Oils for Joint Pain in 2025

February 27, 2025

CBD CoP16 – What is CBD CoP16 and why is it important to rhinos?

October 31, 2024

Boeing expected to maintain El Segundo satellite business

October 31, 2024
Top Posts

Keep your kids safe from marijuana this Halloween

October 31, 2024

Cannabis and professional pickleball form first-ever sponsorship deal

October 30, 2024

Massachusetts cannabis regulator approves new industry rules

October 30, 2024

Flora Growth expands German cannabis presence with Curaleaf deal and parallel import business

October 30, 2024

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

About Us
About Us

Welcome to CannDora’s Box!

At CannDora’s Box, we are passionate about providing you with the latest and most relevant information in the ever-evolving world of cannabis. Our mission is to be your go-to resource for everything related to cannabis culture, including breaking news about cannabis busts, innovative new strains, and the latest in cannabis technology.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

7 Best CBD Capsules of 2025

April 25, 2025

Best CBD Oils for Joint Pain in 2025

February 27, 2025

CBD CoP16 – What is CBD CoP16 and why is it important to rhinos?

October 31, 2024
Most Popular

7 Best CBD Capsules of 2025

April 25, 2025

Greece Wants to Manage Tourists on Overrun Santorini for Summer 2024

January 5, 2020

Country Music Superstar to Host Enormous Concert to Benefit Hall of Fame

January 6, 2020
  • Home
  • About Us
  • Advertise with Us
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
© 2025 canndorasbox. Designed by canndorasbox.

Type above and press Enter to search. Press Esc to cancel.